Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma[1].
in vivo
Vorsetuzumab (10 mg/kg; i.p.; every other day; for 12 d) inhibits Burkitt’s lymphoma cell growth growth in SRG mice[1].
Animal Model:
Burkitt’s lymphoma xenograft model in SRG mice[1]
Dosage:
10 mg/kg
Administration:
Intraperitoneal injection; every other day; for 12 d
Result:
Effectively inhibited Burkitt’s lymphoma cell growth but was not outperform the combination of the KWAR23 antibody (10 mg/kg).
References
[1] Ring NG, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585. DOI:10.1073/pnas.1710877114
